Solvay stock weighs Q3 margin hit against rare-earth supply deal

Solvay reported weaker third-quarter profitability on November 4 as the Middle East conflict disrupted operations and soda ash demand remained soft. At the same time, the chemicals group advanced its rare-earth strategy with a long-term supply agreement with Viridis Mining and Minerals.

The figures and management commentary are set out in Solvay's third-quarter results release. Underlying sales reached EUR 1.031 billion, down 3.3 percent organically from the year-earlier quarter. Underlying EBITDA fell 26.6 percent organically to EUR 173 million, while the margin narrowed to 16.8 percent from 22.2 percent.

Operational pressure remains visible

Solvay attributed about EUR 25 million of the quarterly EBITDA impact to the Middle East conflict. The temporary suspension of the Peroxides plant at the Sadara complex in Jubail, Saudi Arabia, accounted for close to EUR 15 million. The comparison was also affected by about EUR 40 million of carbon-emissions-rights proceeds recorded in the third quarter of 2025.

Underlying net profit from continuing operations fell to EUR 35 million from EUR 90 million a year earlier. Free cash flow to Solvay shareholders from continuing operations reached EUR 54 million in the quarter and EUR 70 million during the first nine months.

Rare-earth supply gains visibility

In a separate company announcement, Solvay said shipments from Viridis' Colossus project in Brazil to its La Rochelle facility in France are expected to start in 2028. The initial term runs through 2034, and committed volumes for key magnetic rare earths represent about 70 percent of anticipated project capacity during that term.

The agreement improves supply visibility for La Rochelle but does not remove development and execution risks linked to the Brazilian project. Solvay is also continuing discussions with OneIM on a possible rare-earth joint venture; no transaction has been completed.

Guidance stays unchanged

Solvay retained its revised 2026 outlook for underlying EBITDA of EUR 720 million to EUR 740 million and free cash flow from continuing operations to shareholders of EUR 120 million to EUR 150 million, net of about EUR 90 million in transformation expenses. Capital expenditure is expected to remain below EUR 300 million, while structural cost savings remain on track for EUR 300 million by year-end.

Solvay company facts

• Company: Solvay S.A.
• ISIN: BE0003470755
• Ticker: SOLB
• Primary listing: Euronext Brussels and Paris
• Q3 2026 underlying EBITDA: EUR 173 million
• 2026 underlying EBITDA outlook: EUR 720 million to EUR 740 million

European chemical-sector developments can be followed in Current market reports.

Further company-specific developments are available in More news and analyses on Solvay stock.